

Atul Pathak

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/550857/publications.pdf>

Version: 2024-02-01

164
papers

6,480
citations

66250

44
h-index

90395

73
g-index

188
all docs

188
docs citations

188
times ranked

9692
citing authors

#	ARTICLE	IF	CITATIONS
1	Predictors of blood pressure response to ultrasound renal denervation in the RADIANCE-HTN SOLO study. <i>Journal of Human Hypertension</i> , 2022, 36, 629-639.	1.0	14
2	Improving the Management of Hypertension by Tackling Awareness, Adherence, and Clinical Inertia: A Symposium Report. <i>American Journal of Cardiovascular Drugs</i> , 2022, 22, 251-261.	1.0	10
3	Clinical Trial Design Principles and Outcomes Definitions for Device-Based Therapies for Hypertension: A Consensus Document From the Hypertension Academic Research Consortium. <i>Circulation</i> , 2022, 145, 847-863.	1.6	28
4	COVID-19, air quality and space monitoring. <i>Geospatial Health</i> , 2022, 17, .	0.3	0
5	Individualized Beta-Blocker Treatment for High Blood Pressure Dictated by Medical Comorbidities: Indications Beyond the 2018 European Society of Cardiology/European Society of Hypertension Guidelines. <i>Hypertension</i> , 2022, 79, 1153-1166.	1.3	20
6	Alcohol-Mediated Renal Sympathetic Neurolysis for the Treatment of Hypertension: The Peregrineâ„¢ Infusion Catheter. <i>Cardiovascular Revascularization Medicine</i> , 2021, 24, 77-86.	0.3	4
7	Re: Arinobu Fukunaga, Takahisa Kawaguchi, Satoshi Funada, et al. Sleep Disturbance Worsens Lower Urinary Tract Symptoms (LUTS): The Nagahama Study. <i>J Urol</i> . In press. https://doi.org/10.1097/JU.000000000000212 . <i>European Urology Focus</i> , 2021, 7, 170-171.	1.6	0
8	Ultrasound renal denervation for hypertension resistant to a triple medication pill (RADIANCE-HTN) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50	0.3	197
9	European Society of Hypertension position paper on renal denervation 2021. <i>Journal of Hypertension</i> , 2021, 39, 1733-1741.	0.3	88
10	Catheter-based alcohol-mediated renal denervation for the treatment of uncontrolled hypertension: design of two sham-controlled, randomized, blinded trials in the absence (TARGET BP OFF-MED) and presence (TARGET BP I) of antihypertensive medications. <i>American Heart Journal</i> , 2021, 239, 90-99.	1.2	16
11	Adherence to Continuous Positive Airway Pressure Hugely Improved during COVID-19 Lockdown in France. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2021, 204, 1103-1106.	2.5	8
12	Long-Term Results up to 12 Months After Catheter-Based Alcohol-Mediated Renal Denervation for Treatment of Resistant Hypertension. <i>Circulation: Cardiovascular Interventions</i> , 2021, 14, e010075.	1.4	8
13	Blood pressure lowering with alcoholâ€­mediated renal denervation using the Peregrine infusion Catheter is independent of injection site location. <i>Catheterization and Cardiovascular Interventions</i> , 2021, 98, E832-E838.	0.7	0
14	Nonhomogeneous force application during typical flutter ablation explains local difficulties in lesion creation. <i>Revista Romana De Cardiologie</i> , 2021, 30, 605-610.	0.0	0
15	Differences in patient and physician perspectives on pharmaceutical therapy and renal denervation for the management of hypertension. <i>Journal of Hypertension</i> , 2021, 39, 162-168.	0.3	29
16	The safety of lasers for BPH surgery in men taking clopidogrel: one cannot judge a book by its cover. <i>World Journal of Urology</i> , 2020, 38, 1081-1082.	1.2	2
17	Medication adherence in hypertension. <i>Journal of Hypertension</i> , 2020, 38, 579-587.	0.3	55
18	Role of Metoprolol Succinate in the Treatment of Heart Failure and Atrial Fibrillation: A Systematic Review. <i>American Journal of Therapeutics</i> , 2020, 27, e183-e193.	0.5	4

#	ARTICLE	IF	CITATIONS
19	Renal Denervation in Hypertensive Patients. <i>Hypertension</i> , 2020, 76, 1084-1086.	1.3	4
20	Impact of COVID-19 lockdown on adherence to continuous positive airway pressure by obstructive sleep apnoea patients. <i>European Respiratory Journal</i> , 2020, 56, 2001607.	3.1	42
21	The interplay between cardiology and diabetology: a renewed collaboration to optimize cardiovascular prevention and heart failure management. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2020, 6, 394-404.	1.4	16
22	Reduction in cardiovascular emergency admissions in Monaco during the COVID-19 pandemic. <i>Clinical Research in Cardiology</i> , 2020, 109, 1577-1578.	1.5	12
23	Observations on changes in ventricular repolarization following four weeks of exercise training in chronic heart failure patients. <i>Scandinavian Cardiovascular Journal</i> , 2020, 54, 369-375.	0.4	1
24	Alcohol-Mediated Renal Denervation Using the Peregrine System Infusion Catheter for Treatment of Hypertension. <i>JACC: Cardiovascular Interventions</i> , 2020, 13, 471-484.	1.1	73
25	Telemonitoring versus standard care in heart failure: a randomised multicentre trial. <i>European Journal of Heart Failure</i> , 2020, 22, 985-994.	2.9	76
26	Using social media to recruit study participants for a randomized trial for hypertension. <i>European Heart Journal Digital Health</i> , 2020, 1, 71-74.	0.7	3
27	Short-term effects of a 3-week interval training program on heart rate variability in chronic heart failure. A randomised controlled trial. <i>Annals of Physical and Rehabilitation Medicine</i> , 2019, 62, 321-328.	1.1	40
28	A Look Beyond Statins and Ezetimibe: a Review of Other Lipid-Lowering Treatments for Cardiovascular Disease Prevention in High-Risk Patients. <i>Current Cardiovascular Risk Reports</i> , 2019, 13, 1.	0.8	1
29	May Measurement Month 2018: a pragmatic global screening campaign to raise awareness of blood pressure by the International Society of Hypertension. <i>European Heart Journal</i> , 2019, 40, 2006-2017.	1.0	193
30	Six-Month Results of Treatment-Blinded Medication Titration for Hypertension Control After Randomization to Endovascular Ultrasound Renal Denervation or a Sham Procedure in the RADIANCE-HTN SOLO Trial. <i>Circulation</i> , 2019, 139, 2542-2553.	1.6	97
31	Is mean heart dose a relevant surrogate parameter of left ventricle and coronary arteries exposure during breast cancer radiotherapy: a dosimetric evaluation based on individually-determined radiation dose (BACCARAT study). <i>Radiation Oncology</i> , 2019, 14, 29.	1.2	98
32	New data, new studies, new hopes for renal denervation in patients with uncontrolled hypertension. <i>International Journal of Cardiology: Hypertension</i> , 2019, 3, 100022.	2.2	0
33	Early detection of subclinical left ventricular dysfunction after breast cancer radiation therapy using speckle-tracking echocardiography: association between cardiac exposure and longitudinal strain reduction (BACCARAT study). <i>Radiation Oncology</i> , 2019, 14, 204.	1.2	27
34	Obstructive sleep apnea syndrome should always be screened in patients complaining of nocturia. <i>World Journal of Urology</i> , 2019, 37, 2801-2802.	1.2	1
35	Structural evidence for a new elaborate 3D-organization of the cardiomyocyte lateral membrane in adult mammalian cardiac tissues. <i>Cardiovascular Research</i> , 2019, 115, 1078-1091.	1.8	7
36	Relationship between nocturia and mortality: are we missing the forest for the trees?. <i>Prostate Cancer and Prostatic Diseases</i> , 2019, 22, 3-4.	2.0	1

#	ARTICLE	IF	CITATIONS
37	Zastosowanie bursztynianu metoprololu w leczeniu niewydolności serca oraz migotania przedsionków: przegląd systematyczny. <i>European Journal of Translational and Clinical Medicine</i> , 2019, 2, 1-20.	0.0	0
38	Impact of sacubitril-valsartan combination in patients with chronic heart failure and sleep apnoea syndrome: the ENTRESTO-SAS study design. <i>ESC Heart Failure</i> , 2018, 5, 222-230.	1.4	19
39	An unusual cause of ventricular flutter. <i>European Heart Journal</i> , 2018, 39, 2015-2015.	1.0	0
40	In Vitro Safety Pharmacology Profiling of Topical β -Adrenergic Agonist Treatments for Erythema of Rosacea. <i>Drugs in R and D</i> , 2018, 18, 87-90.	1.1	4
41	Stopping or maintaining oral anticoagulation in patients undergoing photoselective vaporization of the prostate (SOAP) surgery for benign prostate obstruction: study protocol for a multicentre randomized controlled trial. <i>Trials</i> , 2018, 19, 705.	0.7	4
42	TCT-29 Procedural and anatomic predictors of response in RADIANCE-HTN SOLO: a multicenter, randomized, sham-controlled trial of endovascular ultrasound renal denervation. <i>Journal of the American College of Cardiology</i> , 2018, 72, B13.	1.2	2
43	European Society of Hypertension position paper on renal denervation 2018. <i>Journal of Hypertension</i> , 2018, 36, 2042-2048.	0.3	39
44	Endovascular ultrasound renal denervation to treat hypertension (RADIANCE-HTN SOLO): a multicentre, international, single-blind, randomised, sham-controlled trial. <i>Lancet</i> , 2018, 391, 2335-2345.	6.3	526
45	Intracranial Pressure Is a Determinant of Sympathetic Activity. <i>Frontiers in Physiology</i> , 2018, 9, 11.	1.3	71
46	FOURIER to ODYSSEY: the end of the journey for lipid-lowering therapy trials? Lessons from recent clinical trials with anti-PCSK9 antibodies. <i>EuroIntervention</i> , 2018, 14, 144-146.	1.4	1
47	Will SPYRAL HTN-ON MED change my practice? SPYRAL HTN-ON MED: a prospective, randomised, sham-controlled trial on renal denervation in the presence of antihypertensive medications. <i>EuroIntervention</i> , 2018, 14, e598-e602.	1.4	3
48	Unusually Large Brown tumor of Mandible in a Case of Secondary Hyperparathyroidism Mimicking Cherubism. <i>Indian Journal of Nuclear Medicine</i> , 2018, 33, 132.	0.1	1
49	La recherche en hypertension artérielle en France. <i>Bulletin De L'Academie Nationale De Medecine</i> , 2018, 202, 1571-1579.	0.0	0
50	Interventional procedures and future drug therapy for hypertension. <i>European Heart Journal</i> , 2017, 38, ehw303.	1.0	34
51	Vitamin D deficiency related to physical capacity during cardiac rehabilitation. <i>Annals of Physical and Rehabilitation Medicine</i> , 2017, 60, 2-5.	1.1	2
52	Preoperative right ventricular dysfunction is a strong predictor of 3 years survival after cardiac surgery. <i>Clinical Research in Cardiology</i> , 2017, 106, 734-742.	1.5	40
53	Endothelin contributes to the blood pressure rise triggered by hypoxia in severe obstructive sleep apnea. <i>Journal of Hypertension</i> , 2017, 35, 118-124.	0.3	9
54	Reply. <i>Journal of Hypertension</i> , 2017, 35, 200.	0.3	0

#	ARTICLE	IF	CITATIONS
55	Exercise training-induced modification in autonomic nervous system: An update for cardiac patients. <i>Annals of Physical and Rehabilitation Medicine</i> , 2017, 60, 27-35.	1.1	116
56	Whole-body strength training with Huber Motion Lab and traditional strength training in cardiac rehabilitation: A randomized controlled study. <i>Annals of Physical and Rehabilitation Medicine</i> , 2017, 60, 20-26.	1.1	9
57	Randomised, blinded and controlled comparative study of chemical and radiofrequency-based renal denervation in a porcine model. <i>EuroIntervention</i> , 2017, 12, e1898-e1906.	1.4	27
58	Direct evidence of sympathetic hyperactivity in patients with vasospastic angina. <i>American Journal of Cardiovascular Disease</i> , 2017, 7, 83-88.	0.5	3
59	Prevalence and correlates of coronary heart disease: first population-based study in Lebanon. <i>Vascular Health and Risk Management</i> , 2016, 12, 75.	1.0	30
60	Device-based Therapy for Hypertension. <i>Current Hypertension Reports</i> , 2016, 18, 61.	1.5	40
61	Targeting myocardial reperfusion injuries with cyclosporine in the CIRCUS Trial - pharmacological reasons for failure. <i>Fundamental and Clinical Pharmacology</i> , 2016, 30, 191-193.	1.0	12
62	Early detection and prediction of cardiotoxicity after radiation therapy for breast cancer: the BACCARAT prospective cohort study. <i>Radiation Oncology</i> , 2016, 11, 54.	1.2	62
63	Cardioprotective Angiotensin-(1 α 7) Peptide Acts as a Natural-Biased Ligand at the Angiotensin II Type 1 Receptor. <i>Hypertension</i> , 2016, 68, 1365-1374.	1.3	87
64	Predictors of Uncontrolled Blood Pressure in Treated Hypertensive Individuals: First Population-Based Study in Lebanon. <i>Journal of Clinical Hypertension</i> , 2016, 18, 871-877.	1.0	18
65	Sympathetic nervous response to ischemia-reperfusion injury in humans is altered with remote ischemic preconditioning. <i>American Journal of Physiology - Heart and Circulatory Physiology</i> , 2016, 311, H364-H370.	1.5	41
66	Catheter-based radio-frequency renal nerve denervation lowers blood pressure in obese hypertensive swine model. <i>Journal of Hypertension</i> , 2016, 34, 1854-1862.	0.3	19
67	We are CHARLIE: emotional stress from "Charlie Hebdo attack" extensively relayed by media increases the risk of cardiac events. <i>Clinical Research in Cardiology</i> , 2016, 105, 630-631.	1.5	8
68	Improved Walking Claudication Distance with Transcutaneous Electrical Nerve Stimulation. <i>American Journal of Physical Medicine and Rehabilitation</i> , 2015, 94, 941-949.	0.7	7
69	Association between eprosartan-based hypertension therapy and improvement in cognitive function score: long-term follow-up from the OSCAR observational study. <i>JRAAS - Journal of the Renin-Angiotensin-Aldosterone System</i> , 2015, 16, 366-373.	1.0	4
70	Dual agonist occupancy of AT1-R \pm 2C-AR heterodimers results in atypical Gs-PKA signaling. <i>Nature Chemical Biology</i> , 2015, 11, 271-279.	3.9	83
71	Whole-Body Strength Training Using a Huber Motion Lab in Coronary Heart Disease Patients. <i>American Journal of Physical Medicine and Rehabilitation</i> , 2015, 94, 385-394.	0.7	6
72	Physical activity prescription for improving health in patients with cardiometabolic risk: Using empirical evidence to provide clear public health messages. <i>Annals of Physical and Rehabilitation Medicine</i> , 2015, 58, 305-307.	1.1	0

#	ARTICLE	IF	CITATIONS
73	Renal sympathetic nerve denervation using intraluminal ultrasound within a cooling balloon preserves the arterial wall and reduces sympathetic nerve activity. <i>EuroIntervention</i> , 2015, 11, 477-484.	1.4	38
74	Bortezomib and heart failure: case report and review of the French pharmacovigilance database. <i>Fundamental and Clinical Pharmacology</i> , 2014, 28, 349-352.	1.0	35
75	Low-temperature plasmas at atmospheric pressure: toward new pharmaceutical treatments in medicine. <i>Fundamental and Clinical Pharmacology</i> , 2014, 28, 123-135.	1.0	97
76	Management of hypertension in adults: the 2013 French Society of Hypertension guidelines. <i>Fundamental and Clinical Pharmacology</i> , 2014, 28, 1-9.	1.0	72
77	Atomic force and electron microscopic-based study of sarcolemmal surface of living cardiomyocytes unveils unexpected mitochondrial shift in heart failure. <i>Journal of Molecular and Cellular Cardiology</i> , 2014, 74, 162-172.	0.9	27
78	Direct Evidences for Sympathetic Hyperactivity and Baroreflex Impairment in Tako Tsubo Cardiopathy. <i>PLoS ONE</i> , 2014, 9, e93278.	1.1	54
79	From SYMPPLICITY HTN-3 to the Renal Denervation Global Registry: where do we stand and where should we go?. <i>EuroIntervention</i> , 2014, 10, 21-23.	1.4	26
80	First report of transradial renal denervation with the dedicated radiofrequency Iberis catheter. <i>EuroIntervention</i> , 2014, 9, 1385-1388.	1.4	15
81	Renal denervation: A plea for wisdom. <i>Archives of Cardiovascular Diseases</i> , 2013, 106, 121-123.	0.7	7
82	Sympathetic and vascular dysfunction in adult patients with Fontan circulation. <i>International Journal of Cardiology</i> , 2013, 167, 1333-1338.	0.8	58
83	Transcatheter Aortic Valve Implantation Reduces Sympathetic Activity and Normalizes Arterial Spontaneous Baroreflex in Patients With Aortic Stenosis. <i>JACC: Cardiovascular Interventions</i> , 2013, 6, 1195-1202.	1.1	27
84	TCT-123 Preliminary safety and efficacy results from the REALISE trial: RENAL denervation by ultraSound transcatheter Emission. <i>Journal of the American College of Cardiology</i> , 2013, 62, B40.	1.2	3
85	Association Between Elevated Blood Glucose and Outcome in Acute Heart Failure. <i>Journal of the American College of Cardiology</i> , 2013, 61, 820-829.	1.2	111
86	Cardiorenal anemia syndrome in chronic heart failure contributes to increased sympathetic nerve activity. <i>International Journal of Cardiology</i> , 2013, 168, 2352-2357.	0.8	14
87	Incremental value of biomarkers to clinical variables for mortality prediction in acutely decompensated heart failure: The Multinational Observational Cohort on Acute Heart Failure (MOCA) study. <i>International Journal of Cardiology</i> , 2013, 168, 2186-2194.	0.8	207
88	Design and methodology of POWER, an open-label observation of the effect of primary care interventions on total cardiovascular risk in patients with hypertension. <i>Fundamental and Clinical Pharmacology</i> , 2013, 27, 210-215.	1.0	6
89	High-Intensity Interval Exercise Improves Vagal Tone and Decreases Arrhythmias in Chronic Heart Failure. <i>Medicine and Science in Sports and Exercise</i> , 2013, 45, 1861-1867.	0.2	50
90	Management of arterial hypertension in adults: 2013 guidelines of the French Society of Arterial Hypertension. <i>Sang Thrombose Vaisseaux</i> , 2013, 25, 297-305.	0.1	7

#	ARTICLE	IF	CITATIONS
91	Effect of Antihypertensive Therapy on SCORE-Estimated Total Cardiovascular Risk: Results from an Open-Label, Multinational Investigationâ€™The POWER Survey. <i>International Journal of Hypertension</i> , 2013, 2013, 1-8.	0.5	3
92	Arterial Hypertension and Resistance to Antihypertensive Treatment: a New Adverse Drug Reaction with Modafinil. <i>Therapie</i> , 2013, 68, 53-54.	0.6	4
93	Cardiac Fibroblasts Regulate Sympathetic Nerve Sprouting and Neurocardiac Synapse Stability. <i>PLoS ONE</i> , 2013, 8, e79068.	1.1	17
94	Acute electromyostimulation Decreases Muscle Sympathetic Nerve Activity in Patients with Advanced Chronic Heart Failure (EMSICA Study). <i>PLoS ONE</i> , 2013, 8, e79438.	1.1	15
95	Deciphering biased-agonism complexity reveals a new active AT1 receptor entity. <i>Nature Chemical Biology</i> , 2012, 8, 622-630.	3.9	182
96	Mineralocorticoid receptor antagonists for heart failure with reduced ejection fraction: integrating evidence into clinical practice. <i>European Heart Journal</i> , 2012, 33, 2782-2795.	1.0	148
97	Peripheral chemoreflex activation contributes to sympathetic baroreflex impairment in chronic heart failure. <i>Journal of Hypertension</i> , 2012, 30, 753-760.	0.3	70
98	Valvular heart disease in a patient taking 3,4â€™methylendioxyamphetamine (MDMA, â€™Ecstasyâ€™™). <i>British Journal of Clinical Pharmacology</i> , 2012, 74, 547-548.	1.1	13
99	Impact of chronic obstructive pulmonary disease severity on symptoms and prognosis in patients with systolic heart failure. <i>Clinical Research in Cardiology</i> , 2012, 101, 717-726.	1.5	21
100	Effect of eprosartan-based therapy on systolic blood pressure and total cardiovascular risk in a large international population: preliminary report of the observational POWER study. <i>Vascular Health and Risk Management</i> , 2012, 8, 563.	1.0	5
101	Telephone Support Oriented by Accelerometric Measurements Enhances Adherence to Physical Activity Recommendations in Noncompliant Patients After a Cardiac Rehabilitation Program. <i>Archives of Physical Medicine and Rehabilitation</i> , 2012, 93, 2141-2147.	0.5	46
102	Non-steroidal anti-inflammatory drugs (NSAIDs) and hypertension treatment intensification: a population-based cohort study. <i>European Journal of Clinical Pharmacology</i> , 2012, 68, 1533-1540.	0.8	40
103	Ephrin-B1 Is a Novel Specific Component of the Lateral Membrane of the Cardiomyocyte and Is Essential for the Stability of Cardiac Tissue Architecture Cohesion. <i>Circulation Research</i> , 2012, 110, 688-700.	2.0	30
104	Blood Pressure Responses to Hypertension Treatment and Trends in Cognitive Function in Patients With Initially Difficultâ€™toâ€™Treat Hypertension: A Retrospective Subgroup Analysis of the Observational Study on Cognitive Function and SBP Reduction (OSCAR) Study. <i>Journal of Clinical Hypertension</i> , 2012, 14, 78-84.	1.0	9
105	A Prehospital Acute Coronary Syndrome in a Cocaine User: An Unstable Clinical Situation. <i>Journal of Medical Toxicology</i> , 2012, 8, 80-82.	0.8	0
106	Eprosartan-based hypertension therapy, systolic arterial blood pressure and cognitive function: analysis of Middle East data from the OSCAR study. <i>Vascular Health and Risk Management</i> , 2011, 7, 491.	1.0	9
107	QT interval prolongation: prevalence, risk factors and pharmacovigilance data among methadone-treated patients in France. <i>Fundamental and Clinical Pharmacology</i> , 2011, 25, 503-510.	1.0	33
108	Prescribed drugs and violence: a case/noncase study in the French Pharmacovigilance Database. <i>European Journal of Clinical Pharmacology</i> , 2011, 67, 1189-1198.	0.8	22

#	ARTICLE	IF	CITATIONS
109	Giant Cell Arteritis as a Cause of Acute Myocarditis in the Elderly. <i>Journal of Rheumatology</i> , 2011, 38, 2497-2497.	1.0	11
110	Clinical, Angiographic, and Genetic Factors Associated With Early Coronary Stent Thrombosis. <i>JAMA - Journal of the American Medical Association</i> , 2011, 306, 1765-74.	3.8	179
111	Blood Signature of Pre-Heart Failure: A Microarrays Study. <i>PLoS ONE</i> , 2011, 6, e20414.	1.1	23
112	Bleedings Induced by Oral Anticoagulants: a Study of Adverse Drug Reactions Reported to Midi-Pyrénées Pharmacovigilance Centre Between 2003 and 2006. <i>Therapie</i> , 2010, 65, 567-569.	0.6	2
113	Activation of catalase by apelin prevents oxidative stress-linked cardiac hypertrophy. <i>FEBS Letters</i> , 2010, 584, 2363-2370.	1.3	125
114	PEI-alginate nanocomposites: Efficient non-viral vectors for nucleic acids. <i>International Journal of Pharmaceutics</i> , 2010, 385, 194-202.	2.6	40
115	Cross-linked polyethylenimine-hexametaphosphate nanoparticles to deliver nucleic acids therapeutics. <i>Nanomedicine: Nanotechnology, Biology, and Medicine</i> , 2010, 6, 344-354.	1.7	23
116	Drugs and dilated cardiomyopathies: a case/noncase study in the French Pharmacovigilance Database. <i>British Journal of Clinical Pharmacology</i> , 2010, 69, 287-294.	1.1	37
117	Levosimendan improves hemodynamics functions without sympathetic activation in severe heart failure patients: Direct evidence from sympathetic neural recording. <i>Acute Cardiac Care</i> , 2010, 12, 25-30.	0.2	10
118	Tonic Chemoreflex Activation Contributes to Increased Sympathetic Nerve Activity in Heart Failure-Related Anemia. <i>Hypertension</i> , 2010, 55, 1012-1017.	1.3	35
119	Limited prognostic value of cardiac metaiodobenzylguanidine in advanced heart failure. <i>Journal of Heart and Lung Transplantation</i> , 2010, 29, 591-592.	0.3	2
120	High Maintenance Dosage of Clopidogrel is Associated with a Reduced Risk of Stent Thrombosis in Clopidogrel-Resistant Patients. <i>American Journal of Cardiovascular Drugs</i> , 2010, 10, 29-35.	1.0	18
121	Improvement of Young and Elderly Patient's Knowledge of Heart Failure after an Educational Session. <i>Clinical Medicine Cardiology</i> , 2009, 3, CMC.S2357.	0.1	4
122	Dextropropoxyphene withdrawal from a French university hospital: impact on analgesic drug consumption. <i>Fundamental and Clinical Pharmacology</i> , 2009, 23, 247-252.	1.0	22
123	Recent trends in non-viral vector-mediated gene delivery. <i>Biotechnology Journal</i> , 2009, 4, 1559-1572.	1.8	161
124	Gene Expression, Biodistribution, and Pharmacoscintigraphic Evaluation of Chondroitin Sulfate~PEI Nanoconstructs Mediated Tumor Gene Therapy. <i>ACS Nano</i> , 2009, 3, 1493-1505.	7.3	111
125	Tesofensine and weight loss. <i>Lancet, The</i> , 2009, 373, 719.	6.3	3
126	Excessive sympathetic activation in heart failure with chronic renal failure: role of chemoreflex activation. <i>Journal of Hypertension</i> , 2009, 27, 1849-1854.	0.3	40

#	ARTICLE	IF	CITATIONS
127	Efficient Tumor Targeting by Polysaccharide Decked Polyethylenimine Based Nanocomposites. Journal of Biomedical Nanotechnology, 2009, 5, 264-277.	0.5	13
128	Sympathoexcitation Increases the QT/RR Slope in Healthy Men: Differential Effects of Hypoxia, Dobutamine, and Phenylephrine. Journal of Cardiovascular Electrophysiology, 2008, 19, 178-184.	0.8	12
129	Case ascertainment and estimated incidence of drug-induced long QT syndrome: study in Southwest France. British Journal of Clinical Pharmacology, 2008, 66, 386-395.	1.1	62
130	Myocardial infarction, heart failure and sympathetic nervous system activity: new pharmacological approaches that affect neurohumoral activation. Expert Opinion on Investigational Drugs, 2008, 17, 1315-1330.	1.9	22
131	Effects of enoximone on peripheral and central chemoreflex responses in humans. American Journal of Physiology - Heart and Circulatory Physiology, 2008, 294, H322-H329.	1.5	2
132	Effects of hypertension therapy based on eprosartan on systolic arterial blood pressure and cognitive function: primary results of the Observational Study on Cognitive function And Systolic Blood Pressure Reduction open-label study. Journal of Hypertension, 2008, 26, 1642-1650.	0.3	66
133	Perception of teratogenic and foetotoxic risk by health professionals: a survey in Midi-Pyrenees area. Pharmacy Practice, 2008, 6, 15-9.	0.8	18
134	Nano-vectors for efficient liver specific gene transfer. International Journal of Nanomedicine, 2008, 3, 31-49.	3.3	23
135	Adrenomedullin Inhibits Adipogenesis Under Transcriptional Control of Insulin. Diabetes, 2007, 56, 553-563.	0.3	29
136	Biotherapies: Are they Just Like any Other Drugs?. Therapie, 2007, 62, 235-239.	0.6	2
137	N-(Iodoacetyl)-N-(anthraquinon-2-oyl)-ethylenediamine (IAED): A New Heterobifunctional Reagent for the Preparation of Biochips. Bioconjugate Chemistry, 2007, 18, 8-12.	1.8	16
138	A unique and highly efficient non-viral DNA/siRNA delivery system based on PEI-bisepoxide nanoparticles. Biochemical and Biophysical Research Communications, 2007, 362, 835-841.	1.0	69
139	Interactions médicamenteuses chez le cardiaque traité. Archives Des Maladies Du Coeur Et Des Vaisseaux - Pratique, 2007, 2007, 13-16.	0.0	0
140	In vivo pharmacodynamic interactions between two drugs used in orthostatic hypotension ? midodrine and dihydroergotamine. Fundamental and Clinical Pharmacology, 2007, 21, 45-53.	1.0	5
141	Rationale, design and methods of the OSCAR study: observational study on cognitive function and systolic blood pressure reduction in hypertensive patients. Fundamental and Clinical Pharmacology, 2007, 21, 199-205.	1.0	14
142	Coxibs: evolution of prescription's behaviour in France. Fundamental and Clinical Pharmacology, 2007, 21, 317-325.	1.0	1
143	Blood pressure disorders during Parkinson's disease: epidemiology, pathophysiology and management. Expert Review of Neurotherapeutics, 2006, 6, 1173-1180.	1.4	53
144	Chemoreflex and Metaboreflex Responses to Static Hypoxic Exercise in Aging Humans. Medicine and Science in Sports and Exercise, 2006, 38, 305-312.	0.2	39

#	ARTICLE	IF	CITATIONS
145	Dynamic Ventricular Repolarisation: From Physiology to Prognosis. <i>Current Cardiology Reviews</i> , 2006, 2, 283-286.	0.6	1
146	Dose-dependent effect of dobutamine on chemoreflex activity in healthy volunteers. <i>British Journal of Clinical Pharmacology</i> , 2006, 62, 272-279.	1.1	19
147	Sympathetic control after cardiac resynchronization therapy: responders versus nonresponders. <i>American Journal of Physiology - Heart and Circulatory Physiology</i> , 2006, 291, H2647-H2652.	1.5	48
148	Acute Cardiovascular and Sympathetic Effects of Nicotine Replacement Therapy. <i>Hypertension</i> , 2006, 47, 1162-1167.	1.3	73
149	ApoO, a Novel Apolipoprotein, Is an Original Glycoprotein Up-regulated by Diabetes in Human Heart. <i>Journal of Biological Chemistry</i> , 2006, 281, 36289-36302.	1.6	70
150	Heat-related morbidity in patients with orthostatic hypotension and primary autonomic failure. <i>Movement Disorders</i> , 2005, 20, 1213-1219.	2.2	27
151	Adverse drug reactions related to drugs used in orthostatic hypotension: a prospective and systematic pharmacovigilance study in France. <i>European Journal of Clinical Pharmacology</i> , 2005, 61, 471-474.	0.8	33
152	QT dynamicity: a prognostic factor for sudden cardiac death in chronic heart failure. <i>European Journal of Heart Failure</i> , 2005, 7, 269-275.	2.9	47
153	The vasoactive peptide adrenomedullin is secreted by adipocytes and inhibits lipolysis through NO-mediated β_2 -adrenergic agonist oxidation. <i>FASEB Journal</i> , 2005, 19, 1045-1047.	0.2	33
154	Kinetic analysis of cardiac transcriptome regulation during chronic high-fat diet in dogs. <i>Physiological Genomics</i> , 2004, 19, 32-40.	1.0	22
155	Uncomplicated human obesity is associated with a specific cardiac transcriptome: involvement of the Wnt pathway. <i>FASEB Journal</i> , 2004, 18, 1539-1540.	0.2	17
156	Intestinal obstruction associated with oral midodrine. <i>Clinical Autonomic Research</i> , 2004, 14, 202-3.	1.4	5
157	New concerns about old drugs: Valvular heart disease on ergot derivative dopamine agonists as an exemplary situation of pharmacovigilance. <i>Movement Disorders</i> , 2004, 19, 611-613.	2.2	46
158	Dopaminagonists and fibrotic valvular heart disease: Further considerations. <i>Movement Disorders</i> , 2004, 19, 1524-1525.	2.2	19
159	Pharmacology of orthostatic hypotension in Parkinson's disease: from pathophysiology to management. <i>Expert Review of Cardiovascular Therapy</i> , 2004, 2, 393-403.	0.6	18
160	Adrenomedullin upregulates M2 -muscarinic receptors in cardiomyocytes from P19 cell line. <i>British Journal of Pharmacology</i> , 2003, 139, 1219-1227.	2.7	4
161	Cardiac Transcriptome Analysis in Obesity-Related Hypertension. <i>Hypertension</i> , 2003, 41, 414-421.	1.3	43
162	Garlic Interaction with Fluindione: A Case Report. <i>Therapie</i> , 2003, 58, 380-381.	0.6	22

#	ARTICLE	IF	CITATIONS
163	Rehabilitation of patients with congestive heart failure with or without β -blockade therapy. Journal of Cardiac Failure, 2001, 7, 241-248.	0.7	21
164	Prognostic value of heart rate variability in time domain analysis in congestive heart failure. Journal of Interventional Cardiac Electrophysiology, 2001, 5, 181-187.	0.6	47